Lijing Chen

USPTO Granted Patents = 16 (Patent Applications = 8)

EPO Patents = 4 (Patent Applications = 12)

Average Co-Inventor Count = 4.7

ph-index = 5

Forward Citations = 71(Granted Patents)

Company Filing History:

12 out of 30

Calithera Biosciences, Inc.

Antengent Therapeutics Limited

patent

4. 1 out of 1

Precision Pharmaceuticals, Inc.

patent

5. 1 out of 1

Antengene Therapeutics Limited

patent

Years Active: 2010-2025

Loading Chart...

16 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12421273 - Ectonucleotidase inhibitors and methods of use thereof (2025-09-23),

2. 12054501 - Compositions and methods for inhibiting arginase activity (2024-08-06),

3. 11858957 - Ectonucleotidase inhibitors and methods of use thereof (2024-01-02),

4. 11208414 - Ectonucleotidase inhibitors and methods of use thereof (2021-12-28),

5. 11078228 - Ectonucleotidase inhibitors and methods of use thereof (2021-08-03),

6. 11034715 - Ectonucleotidase inhibitors and methods of use thereof (2021-06-15),

7. 11021495 - Compositions and methods for inhibiting arginase activity (2021-06-01),

8. 10793535 - Heterocyclic glutaminase inhibitors (2020-10-06),

9. 10597411 - Compositions and methods for inhibiting arginase activity (2020-03-24),

10. 10570167 - Ectonucleotidase inhibitors and methods of use thereof (2020-02-25),

11. 10472364 - Ectonucleotidase inhibitors and methods of use thereof (2019-11-12),

12. 10287303 - Compositions and methods for inhibiting arginase activity (2019-05-14),

13. 9938267 - Heterocyclic inhibitors of glutaminase (2018-04-10),

14. 8865718 - Heterocyclic inhibitors of glutaminase (2014-10-21),

15. 8604016 - Heterocyclic inhibitors of glutaminase (2013-12-10),

Title: **Lijing Chen: Innovator in Cancer Treatment**

Introduction

Lijing Chen, an accomplished inventor based in Cupertino, CA, has made significant contributions to the field of pharmaceuticals, particularly in developing innovative methods to combat cancer. With a remarkable portfolio of 15 patents, Chen's work continues to pave the way for advancements in medical treatments.

Latest Patents

Among her latest patents are groundbreaking inventions aimed at inhibiting arginase activity. This novel class of compounds demonstrates effective inhibitory activity toward arginase and includes pharmaceutical compositions designed to treat cancer using these inhibitors. Additionally, Chen has developed ectonucleotidase inhibitors, which are novel heterocyclic compounds and pharmaceutical preparations that can potentially treat or prevent cancer.

Career Highlights

Lijing Chen has held positions in notable companies such as Calithera Biosciences, Inc. and Wyeth. Her expertise in pharmaceutical innovation has proven invaluable in these organizations, where she has contributed to various research and development projects.

Collaborations

In her career, Chen has collaborated with prominent colleagues, including Jim W Li and Eric Brian Sjogren. These partnerships have enhanced her ability to drive forward-thinking solutions in the medical field, particularly in cancer treatment.

Conclusion

Lijing Chen stands out as a remarkable inventor whose contributions have the potential to change the landscape of cancer therapy. Through her innovative patents and collaborations, she exemplifies the spirit of innovation essential in the fight against this pervasive disease. Her work not only highlights the importance of research and development in pharmaceuticals but also inspires future generations of inventors and researchers.

This text is generated by artificial intelligence and may not be accurate.